Abstract
Solifenacin succinate, a competitive muscarinic receptor antagonist, is one of the newer options for the treatment of overactive bladder in men and women.
Objective:
To review the pharmacology, efficacy and tolerability for the treatment of overactive bladder with solifenacin succinate.
Methods:
A literature search was done using the keywords YM905 and solifenacin succinate.
Conclusion:
Solifenacin succinate was shown to be effective for symptom control with an increase in volume voided, improvement in quality of life and a decrease in a common side effect of dry mouth compared to other medications.
MeSH terms
-
Animals
-
Clinical Trials as Topic
-
Female
-
Humans
-
Male
-
Muscarinic Antagonists / administration & dosage*
-
Muscarinic Antagonists / adverse effects
-
Muscarinic Antagonists / pharmacokinetics
-
Quality of Life
-
Quinuclidines / administration & dosage*
-
Quinuclidines / adverse effects
-
Quinuclidines / pharmacokinetics
-
Solifenacin Succinate
-
Tetrahydroisoquinolines / administration & dosage*
-
Tetrahydroisoquinolines / adverse effects
-
Tetrahydroisoquinolines / pharmacokinetics
-
Urinary Bladder, Overactive / drug therapy*
Substances
-
Muscarinic Antagonists
-
Quinuclidines
-
Tetrahydroisoquinolines
-
Solifenacin Succinate